Familial hereditary cardiac myxoma: report of three cases and literature review Authors: Qian Yao, Bin Zhan, Huimin Liu, Liu Luo, Lin Tang Published: 2025 ABSTRACT AbstractBackgroundCardiac myxoma, the most common primary benign cardiac tumor, carries a risk of embolization and can be life-threatening. It typically arises in the left atrium but may involve any cardiac chamber. Myxomas may occur sporadically, have familial origins, or present as part of Carney’s syndrome.Case presentationThree cases of cardiac myxoma are presented; two involved a father-daughter pair with familial myxoma, while one patient presented with acute exacerbation and was diagnosed postoperatively. Echocardiography and Computed Tomography Angiography (CTA) revealed intracardiac space-occupying lesions suggestive of myxoma. Elective atrial resection was performed under cardiopulmonary bypass; histopathology confirmed the diagnosis. Genetic testing identified a Protein Kinase cAMP-Dependent Type I Regulatory Subunit Alpha (PRKAR1A) gene mutation.ConclusionsPaternal-to-daughter transmission of PRKAR1A mutations is uncommon compared with typical familial cardiac myxomas. All three cases in this series represent this transmission pattern. Surgical resection resulted in a favorable recovery without sequelae. Timely diagnosis and intervention are essential to prevent complications, and regular follow-up is necessary to detect recurrence. This study reports three cases of familial cardiac myxoma and includes a literature review.Keywords: Myxoma, Familial inheritance, Cardiac myxoma, Carney's syndrome, Cardiac tumor Introduction Although cardiac myxomas are biologically benign, they demonstrate “functional” malignancy due to their embolic potential, which can result in life-threatening events [1]. They may mimic connective tissue or inflammatory disorders, underscoring the need for timely diagnosis and surgical resection. Familial hereditary cardiac myxoma is a rare genetic disorder associated with specific gene mutations. Clinicians should remain vigilant to enable early recognition and definitive surgical management. This report presents three cases of familial hereditary cardiac myxoma and reviews current research to provide a reference for diagnosis and treatment. Case presentation Case 1 A 70-year-old man presented with “cough, chest distress, and discomfort” at an external hospital.The patient had a history of previous thoracic wall surgery and left upper limb dysfunction caused by cerebral infarction. After hospitalization, the patient improved and has been taking “aspirin enteric tablets” regularly.Cardiac ultrasound revealed a slightly hyperechoic mass in the left atrium and mitral valve, suggestive of myxoma. The patient was admitted to our hospital on November 25, 2024, for further diagnosis and treatment. Comprehensive assessment, including medical history, clinical manifestations, family history (Table 1), and imaging examinations— Computed Tomography Angiography (CTA; Table 1, Figure A) and echocardiography (Table 2)—led to the following diagnoses: ① Left atrial space-occupying lesion: myxoma; ② Valvular heart disease - mitral, aortic, and tricuspid regurgitation with cardiac dilatation and cardiac function class II; ③ Old cerebral infarction. After preoperative preparation, the patient underwent cardiac tumor resection with tricuspid valvuloplasty under general anesthesia with extracorporeal circulation on November 30, 2024. Intraoperative findings are shown in Table 2; Fig. 1C. Postoperative histopathology confirmed myxoma (Table 2; Fig. 1D), and genetic testing detected a Protein Kinase cAMP-Dependent Type I Regulatory Subunit Alpha (PRKAR1A) mutation (Table 2). The patient was discharged on postoperative day 20 with good recovery and has remained complication-free. Table 1Medical history, clinical manifestations, family history, and CTA findings of three patientsAnamnesisClinical ManifestationsFamily HistoryComputed Tomography Angiography (CTA)Case 1Chest wall surgery, old cerebral infarctionRecurrent cough, chest distress, and dyspnea for 1 yearDaughter (Case 2) with cardiac myxomaA 68 mm×40 mm filling defect with smooth margins in the left atrium, extending to the mitral valve orifice; an additional broad-based pedicle (20 mm×17 mm) attached to the anterosuperior atrial wall (Fig. 1A).Case 2Surgery for accessory breast tissue (right) and pelvic cystNoneFather (Case 1) with cardiac myxomaLeft atrial enlargement with a 70 mm×40 mm filling defect containing irregular septations and scalloped margins, extending to the mitral orifice (Fig. 1E).Case 3NoneRecurrent chest distress, palpitation, and dyspnea for 1 month, aggravated over the past week.Father had a cardiac myxoma, declined surgical treatment, and died 2 years later.Enlarged left atrium with a 60 mm x 36 mm filling defect at the interatrial septum and the anterior atrial wall; during diastole, the mass partially prolapsed into the left ventricle via the mitral valve (Fig. 1I). Medical history, clinical manifestations, family history, and CTA findings of three patients Table 2Echocardiography, intraoperative findings, pathology, and genetic testing of three patientsEchocardiographyIntraoperative FindingsPathological FindingsGenetic TestingCase 1Left atrial enlargement with a pedunculated hyperechoic mass (72 mm×42 mm) attached to the mid-interatrial septum, swinging with the cardiac cycle and prolapsing into the mitral orifice during diastole (Fig. 1B).Tumors measuring approximately 4 cm×3 cm and 8 cm×6 cm, located on the superior and inferior left atrial surfaces of the interatrial septum, respectively. Both pedicles arose from the septum. Tumors were soft, friable, with translucent granular protrusions resembling Vitis vinifera. An additional tumor measuring approximately 2 cm×1 cm at the posterior mitral leaflet –chordal junction showed similar morphology (Fig. 1C).Fibromyxoid degeneration with small cell clusters, consistent with atrial myxoma (Fig. 1D)PRKAR1A mutation at locus 17q22-24Case 2Global cardiac enlargement with a lobulated hyperechoic mass (measuring approximately 77 mm×37 mm) formed by two confluent components, pedicle attached to the mid-interatrial septum, swinging with the cardiac cycle and extending to the mitral valve orifice during diastole (Fig. 1 F).Tumors on the superior and inferior left atrial surfaces of the interatrial septum (approximately 5 cm×4 cm and 7 cm×6 cm, respectively). Pedicles originated from the septum. Tumors were soft, friable, with translucent granular protrusions resembling Vitis vinifera.(Fig. 1G).Left atrial myxoma with regional necrosis (Fig. 1H)PRKAR1A mutation at locus 17q22-24Case 3Left atrial enlargement with a hyperechoic mass (measuring approximately 66 mm×30 mm) attached by a 4 mm stalk to the mid-interatrial septum, swinging with the cardiac cycle and prolapsing into the mitral orifice during diastole (Fig. 1 J).A tumor measuring approximately 7 cm×5 cm on the left atrial aspect of the upper interatrial septum, with a pedicle arising from the septum. The tumor was soft, friable, with translucent granular protrusions resembling Vitis vinifera (Fig. 1K).Left atrial myxoma with stromal vascular dilation hemorrhage (Fig. 1L)PRKAR1A mutation at the C.491-492delTG locus Echocardiography, intraoperative findings, pathology, and genetic testing of three patients CTA, cardiac Doppler ultrasound, intraoperative gross specimen of the mass, and HE pathological images of the three patients. A-D correspond to the sagittal CTA, ultrasonographic findings, surgical specimen images, and HE pathological results of Case 1, respectively; E-H correspond to the sagittal CTA, ultrasonographic findings, surgical specimen images, and HE pathological results of Case 2, respectively; I-L correspond to the sagittal CTA, ultrasonographic findings, surgical specimen images, and HE pathological results of Case 3, respectively Case 2 A 42-year-old female patient was admitted on December 6, 2024, after a “left atrial mass” was detected on cardiac ultrasound during a routine health checkup, one day following her father’s (Case 1) diagnosis of cardiac myxoma and surgical resection. Relevant medical history, clinical findings, and family history are provided in Table 1. CTA (Table 1, Fig. 1E) and echocardiography (Table 2, Fig. 1F) confirmed a diagnosis of “giant left atrial myxoma.” On December 7, 2024, she underwent elective cardiac tumor resection with mitral valvoplasty, tricuspid valvuloplasty, and closure of the coronary artery-right atrial fistula under general anesthesia with extracorporeal circulation. Intraoperative findings are documented in Tables 2 and Fig. 1G. Postoperative histopathology confirmed myxoma (Fig. 1H), and genetic testing identified a PRKAR1A mutation (Table 2). The patient was discharged on postoperative day 12 with complete recovery and has remained free of complications during follow-up. Case 3 A 52-year-old female patient presented to the emergency department on December 26, 2024, with “chest distress and palpitation for over a month and a left atrial mass” identified 6 days earlier. Past medical history, clinical manifestations, and family history are summarized in Table 1. Emergency CTA (Table 1, Fig. 1I) and echocardiography (Table 2, Fig. 1J) established the diagnoses: ① left atrial myxoma. On the same day, she underwent emergency cardiac tumor resection with mitral valvoplasty under general anesthesia with extracorporeal circulation. Intraoperative details are shown in (Tables 2, Fig. 1K). Postoperative pathology confirmed myxoma (Fig. 1L). Genetic testing of partial specimens revealed a PRKAR1A mutation at the C.491-492delTG locus (Table 2). The patient was discharged on postoperative day 8 with complete recovery and has remained free of complications during follow-up. Discussion Cardiac myxoma is a benign cardiac tumor that may cause severe “functional” impairment [1, 2]. Approximately 90% are solitary [3], representing nearly 90% of cardiac surgery cases and 50% of cardiovascular medicine cases [4]. Female patients account for approximately 67%, and 75% of myxomas occur in the left atrium near the fossa ovalis [5, 6], while 15%–20% arise in the right atrium [3]. Familial cardiac myxoma represents approximately 10% of cases, frequently presenting as multiple tumors at atypical sites [7]. Although surgical resection is the mainstay of treatment, recurrence remains a concern. Sporadic myxomas recur in 4%–7% of cases, with secondary recurrence rare, whereas familial myxomas recur in 10%–21% [8], frequently with secondary recurrence. Secondary recurrence frequently develops approximately 10 years after the initial operation [9, 10]. Possible mechanisms include [11]: ① incomplete primary excision, following regrowth; ② familial predisposition; ③ spontaneous or surgical implantation of tumor fragments into myocardium; ④ pre-tumor lesions in other myocardial sites. Even with complete excision, recurrence occurs in approximately 20%, due to residual or new lesions [12]. Accordingly, patients in this study require echocardiographic follow-up every 6–12 months.Case 1 developed left upper limb dysfunction following cerebral infarction. Although standardized treatment led to functional recovery and improvement in the left arm, secondary symptoms caused by myxoma embolism could not be ruled out. Therefore, three patients in this study underwent regular stroke and myxoma recurrence risk screenings at 1 month, 3 months, and 6 months post-surgery. In the second year after surgery, we conducted 12-month periodic screenings based on existing literature references [13, 14]. Cardiac myxoma, the most common cardiac tumor [8], is typically pedunculated and attached to the interatrial septum of the left atrium [11]. Less commonly, it arises from the posterior left atrium, right atrium, ventricles, or valves [15]. Familial myxomas exhibit autosomal incomplete dominant inheritance [9], frequently affecting younger individuals. They are more atypical, recur more regularly, and may present with Carney syndrome, neurofibromatosis (NAME) syndrome, or as non-syndromic familial myxoma [8, 11].Although genetic variations may be more likely to cause thrombotic myxomas, the data are not yet sufficient to draw a conclusion.None of the three patients in this study showed Carney syndrome; instead, all had paternal histories of myxoma and were incidentally diagnosed during examinations or admissions for unrelated conditions. The classic triad of myxoma includes intracardiac obstruction, embolism, and systemic symptoms [1]. Depending on location, size, morphology, and histopathological profile, patients may be asymptomatic, present with typical features, or develop life-threatening emergencies such as systemic inflammation, multiple emboli, or sudden cardiac death [16–18]. Up to 50% of cases are incidentally detected [19, 20]. Approximately one-third of patients develop mucocutaneous myxomas, affecting eyelids, external auditory canal, breasts, or oropharynx [3]. Cardiac tumors occur in 67% of such patients, and 75% display cutaneous pigmentation, including blue nevi, café-au-lait spots, or hypopigmented macules[21–24]. Additional features include freckles (melasma) on the lips, conjunctiva, canthi, and genital mucosa during prepuberty. Endocrine abnormalities may manifest as nodular cortical adenomas, growth hormone- or prolactin-secreting pituitary adenomas, or large-cell calcifying Sertoli cell tumors [3]. Histopathology typically reveals polygonal multipotent mesenchymal cells [25–27], predominantly located in the subendocardial layer of the atria, especially the interatrial septum. Pathologically, myxoma cells are negative for endothelial markers such as keratin but positive for vimentin [26]. Some may also originate from neuroendocrine tissue [28]. These cells can differentiate into fibroblasts, smooth muscle cells, endothelial cells, and neuroendocrine cells [29, 30], and secrete an acid mucopolysaccharide matrix [25]. Differential diagnoses include organized thrombus, papillary fibroelastoma, myxoid sarcoma, angiosarcoma, epithelioid hemangioendothelioma, intimal sarcoma, and myxofibrosarcoma [31]. The diagnosis of familial cardiac myxoma associated with Carney syndrome follows Carney’s criteria, which include 12 clinical features and two supplementary items [3, 8, 12, 32–34]. A diagnosis is established when two clinical symptoms, or two features plus one supplementary item, are present [32]. Consequently, first-degree relatives should undergo screening and close follow-up. However, most cases lack specific manifestations and are incidentally detected during routine health examinations or while evaluating unrelated conditions. Patients with confirmed Carney syndrome require comprehensive screening, including urinary free cortisol measurement, testicular ultrasonography, and assessment of potential myxoma sites [3]. Routine echocardiography of first-degree relatives is the most effective strategy for detecting familial cardiac myxomas. Echocardiography remains the cornerstone of diagnosis, with computed tomography (CT) and magnetic resonance imaging (MRI) serving as useful adjuncts. Conversely, chest X-ray and electrocardiography have limited diagnostic value, while histopathology remains definitive. Approximately 75% of familial cardiac myxomas follow an autosomal dominant inheritance pattern, with the remaining 25% arising from de novo mutations [35]. Most are caused by inactivating mutations or large deletions of the PRKAR1A gene on 17q22-24. Genetic testing confirmed a mutation at this locus in the present case, underscoring its critical role in evaluating familial myxoma cases. Surgical resection remains the primary treatment for cardiac myxoma and significantly reduces the risk of tumor embolism [1, 36]. The procedure entails excision of the tumor’s pedicle at its base along with the full thickness of the adjacent interatrial septum, followed by closure of the resulting atrial septal defect [1]. Postoperative recurrence occurs in approximately 22% of patients, accounting for over 50% of related mortality [11]. However, data from recent decades indicate that surgical mortality, long-term survival, and recurrence rates remain relatively low [34, 37–53]. In recent years, adopting minimally invasive and robotic-assisted techniques has further improved postoperative outcomes and quality of life [54–57]. During operation, strict vigilance is required to prevent intraoperative embolization from tumor fragment dislodgement. No standardized treatment exists for embolism; however, therapeutic strategies such as open surgery, endovascular coil occlusion, chemotherapy, radiotherapy, and conservative management have been reported [31, 58–60]. Conclusion Although cardiac myxoma is among the most common cardiac tumors, it occurs sporadically in most cases. Familial inherited cardiac myxoma is extremely rare and is frequently associated with Carney syndrome. Despite its benign histology, cardiac myxoma can lead to severe complications, such as intracardiac obstruction and systemic embolism. Echocardiography is invaluable for diagnosis, yet the condition generally lacks specific clinical symptoms, delaying recognition. Surgical resection remains the treatment of choice, followed by long-term surveillance to detect recurrence. Clinicians must maintain a high index of suspicion and apply appropriate diagnostic and therapeutic strategies to ensure timely intervention, thereby minimizing the morbidity and mortality rates in affected patients. Acknowledgements We thank the patients described for allowing us to share his details. Authors’ contributions Qian Yao and Bin Zhan: Design, data gathering, writing and follow-up; Liu Luo: Participate in coronary intervention, Providing fundings and supervision.Huimin Liu: Participate in coronary intervention, review.Lin Tang:,writing and follow-up, Participate in coronary intervention, Revision, review. All the authors are personally accountable for their own contributions. All the authors have read and approved the final manuscript. Funding The case report was supported by Natural Science Foundation of Hunan Province (2025JJ70045). Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate Written informed consent was obtained from the patient. Consent for publication Written informed consent for publication was obtained from participants. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.